{"entity":{"id":"fgf13","kind":"target","name":"FGF13","aka":["fibroblast growth factor 13","Fibroblast growth factor 13","FHF2","FGF2","FLJ30672","LINC00889"],"tldr":"FGF13 (Fibroblast growth factor 13) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Prostate cancer.","summary":"Microtubule-binding protein which directly binds tubulin and is involved in both polymerisation and stabilisation of microtubules. Through its action on microtubules, may participate in the refinement of axons by negatively regulating axonal and leading processes branching. Plays a crucial role in neuron polarisation and migration in the cerebral cortex and the hippocampus.\n\nCIViC holds 1 clinical evidence item and 0 assertions across 1 variant.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:3670","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3670"},{"label":"UniProt Q92913","url":"https://www.uniprot.org/uniprotkb/Q92913/entry"},{"label":"NCBI Gene 2258","url":"https://www.ncbi.nlm.nih.gov/gene/2258"},{"label":"Ensembl ENSG00000129682","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000129682"}],"tags":["cancer-genes-wave"],"related":["civic"],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":["angiogenic-switch"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC holds 1 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"FGF13","role":["biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:3670","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3670","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q92913","url":"https://www.uniprot.org/uniprotkb/Q92913/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene FGF13","url":"https://civicdb.org/features/1883","note":"1 evidence items, 0 assertions, 1 variants; diseases: Prostate Cancer (GraphQL API, CC0)"}],"distribution":"one-type","specificityNote":"Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA FGF13: RNA tissue enhanced (brain 65 nTPM, skeletal muscle 52 nTPM, tongue 41 nTPM); blood lineage lineage enriched (granulocytes 3 nTPM); no normal tissue stained high. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Prostate cancer); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)","specificitySources":[{"label":"Human Protein Atlas FGF13 tissue","url":"https://www.proteinatlas.org/ENSG00000129682-FGF13/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000129682 associations","url":"https://platform.opentargets.org/target/ENSG00000129682/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:3670","ensembl":"ENSG00000129682","uniprot":"Q92913","entrez":"2258","firstDescribed":1996,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Smallwood P.M. et al, Proc. Natl. Acad. Sci. U.S.A, 1996, \"Fibroblast growth factor (FGF) homologous factors: new members of the FGF family implicated in nervous system development\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/8790420/","biology":"Microtubule-binding protein which directly binds tubulin and is involved in both polymerisation and stabilisation of microtubules. Through its action on microtubules, may participate in the refinement of axons by negatively regulating axonal and leading processes branching. Plays a crucial role in neuron polarisation and migration in the cerebral cortex and the hippocampus. Regulates voltage-gated sodium channel transport and function. May also play a role in MAPK signalling. Required for the development of axonal initial segment-targeting inhibitory GABAergic synapses made by chandelier neurons. Location: Nucleus; Cytoplasm; Cell projection, filopodium; Cell projection, growth cone (UniProt). Locus Xq26.3-q27.1 (HGNC).","whereFound":["Prostate cancer: CIViC evidence names this disease"],"targetClass":"other","prevalence":[]},"route":"/targets/fgf13/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"}],"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"pathway":[{"id":"angiogenic-switch","kind":"pathway","name":"The angiogenic switch & tumour vessels","route":"/pathways/angiogenic-switch/"}]}}